Stock fact sheet · data as of
International Stem Cell Corporation (ISCO): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is ISCO undervalued?
ISCO has a margin of safety of 80%: the stock closed at 0.2700 on 16 Oct 2026 against a GLS average fair value of 1.32. 2 of the 2 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
Only 2 of the nine models produced a value (DCF, 10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files ISCO under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for ISCO
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1.78 | +559% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 0.8590 | +218% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.6831 | -353% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: ISCO passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.8 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are high - ROIC 127.8%, ROE 10.3%, ROA -8.7% - with debt at -0.92 times equity and a free-cash-flow yield of 15.4%.
International Stem Cell Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Biomedical Market 94%, Anti Aging Market 6% (quarter Q2 FY2026).
Institutional ownership scores 5/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | 127.8% |
|---|---|---|---|
| GLS Moat | 1.8 / 10 | ROE | 10.3% |
| Debt / equity | -0.92 | ROA | -8.7% |
| Free-cash-flow yield | 15.4% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 39: No options
ISCO has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 6k shares a day on a market cap of $2M, with a beta of -0.05 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 80% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 3 / 15 | moat 1.8/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 6k shares/day, $2M cap, beta -0.05 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for ISCO in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to International Stem Cell Corporation by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| CELZ Creative Medical Technology Holdings, Inc. | 0.8178 | 2.94 | +72% | 34No options | $2M |
| VRAX Virax Biolabs Group Limited | 1.65 | 14.57 | +89% | 38No options | $2M |
| SPRC SciSparc Ltd. | 3.63 | - | - | 21No options | $2M |
| CLDI Calidi Biotherapeutics, Inc. | 0.8701 | 9.22 | +91% | 33No options | $2M |
| KAPA Kairos Pharma, Ltd. | 0.6706 | 1.64 | +59% | 39No options | $2M |
| BRTX BioRestorative Therapies, Inc. | 1.46 | - | - | 26No options | $2M |
| MBRX Moleculin Biotech, Inc. | 0.3701 | 4.51 | +92% | 36No options | $2M |
| ACUT Accustem Sciences Inc. | 0.1474 | - | - | 23No options | $2M |
| OGEN Oragenics, Inc. | 0.4360 | 1.54 | +72% | 36No options | $2M |
| ONCO Onconetix, Inc. | 0.5480 | 1.38 | +60% | 31No options | $2M |
| ABPO Abpro Holdings, Inc. | 0.4080 | 13.18 | +97% | 39No options | $2M |
| CPMV Mosaic ImmunoEngineering Inc. | 0.3330 | - | - | 23No options | $2M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ISCO
Is ISCO undervalued right now?
By the GLS models, yes: at 0.2700 the stock is 80% below the average fair value of 1.32 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ISCO and what does it mean?
ISCO has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for ISCO?
1.32 per share as of 16 Oct 2026 - the simple average of the 2 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does International Stem Cell Corporation report earnings next?
No upcoming earnings date is recorded for ISCO in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does ISCO have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on ISCO, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.